Paper Details

  1. Home
  2. Paper Details

[New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014].

Author: CornbergM, Höner zu SiederdissenC, MaasoumyB, MannsM P

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Direct-acting antiviral agents (DAA) have shown significant progress in treating hepatitis C virus (HCV) infection. While earlier DAA, such as boceprevir and telaprevir, required combination therapy with pegylated interferon α and ribavirin, newer DAA, such as sofosbuvir and simeprevir, offer simplified treatment options.
Paper Details　
Original Abstract of the Article :
The development of direct-acting antiviral agents (DAA) against the hepatitis C virus (HCV) has seen enormous progress in recent years. In 2011, the first protease inhibitors boceprevir (BOC) and telaprevir (TLV) were approved, which still need to be combined with pegylated interferon α (PEG-IFN α) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00108-013-3416-3

データ提供：米国国立医学図書館（NLM）

The Dawn of Direct-Acting Antivirals for Hepatitis C

[Chronic hepatitis C] is a global health concern, with [millions of people infected]. This research explores the [emerging landscape of direct-acting antiviral agents (DAAs)] for the treatment of [chronic hepatitis C]. The authors highlight the [significant progress in DAA development] since the introduction of [boceprevir and telaprevir] in 2011. The arrival of [sofosbuvir and simeprevir] represents a [major advancement] in [hepatitis C treatment], offering [more effective and less burdensome therapies]. This review provides a [comprehensive overview] of the [latest DAA developments] and their [potential to transform the treatment landscape] for [hepatitis C].

A New Era of Hepatitis C Treatment

This review paints a hopeful picture for [hepatitis C patients], showcasing the [remarkable advancements in DAA development]. The emergence of [sofosbuvir and simeprevir] represents a [paradigm shift in treatment], offering [greater efficacy and improved tolerability]. This progress brings hope to millions affected by [hepatitis C] and [paves the way for a brighter future] in managing this disease.

Navigating the Sands of Hepatitis C Treatment

Imagine a desert traveler, seeking a cure for a debilitating ailment. This review provides a roadmap of the [latest advancements in hepatitis C treatment], showcasing the [potential of DAAs] to transform the landscape of care. The research highlights the [importance of ongoing research and development] in combating this disease, offering hope for a future where [hepatitis C] is no longer a major health concern.

Dr. Camel's Conclusion

This research reminds us that the sands of time are constantly shifting, bringing new discoveries and advancements. The emergence of [DAAs] offers a glimmer of hope for those affected by [hepatitis C], paving the way for more effective and less burdensome therapies. This progress is a testament to the tireless efforts of researchers and clinicians who are dedicated to combating this disease.

Date :
  1. Date Completed 2014-11-21
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24652513

DOI: Digital Object Identifier

10.1007/s00108-013-3416-3

Related Literature

Article Analysis
・Side Effects of boceprevir
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.